Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy. - Wikidata - wikimedia - TriplyDB

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.

http://www.wikidata.org/entity/Q37187292

about

A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy.

P2860

Q41487419-142B4DDF-0B53-455E-8A0E-76AA1DC7F0DA

P2860

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.

http://www.wikidata.org/entity/Q37187292

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Age, Neurological Status MRC S ...... Treated by Chemoradiotherapy.

@en

Age, Neurological Status MRC S ...... Treated by Chemoradiotherapy.

@nl

type

label

Age, Neurological Status MRC S ...... Treated by Chemoradiotherapy.

@en

Age, Neurological Status MRC S ...... Treated by Chemoradiotherapy.

@nl

prefLabel

Age, Neurological Status MRC S ...... Treated by Chemoradiotherapy.

@en

Age, Neurological Status MRC S ...... Treated by Chemoradiotherapy.

@nl

P1433

Q37187292-E33318F3-F525-4743-B3D9-070BE81F7C66

P1476

Q37187292-F72E4B08-918C-48F6-B02E-639FF671EEBF

P2093

Q37187292-0F711E8E-C742-4D3E-8691-74ABA06C3CAB

Q37187292-26B01470-3F40-41B2-8A63-566022A59D36

Q37187292-32925002-89B8-40B0-93A4-932B79717BD6

Q37187292-332AE01F-2DDC-4523-B2AE-D28541A65F98

Q37187292-3DE86BE8-5911-4029-9DA7-882F99BA0FC8

Q37187292-48F87920-2832-4F28-9509-5F368340849F

Q37187292-53971846-432B-4CA7-BF3B-2ECD56C11CFC

Q37187292-5A8EE89E-E0A5-40C8-AC98-6F9F5C907B25

Q37187292-5C85A257-D6C0-468A-B3E8-D788709ECE71

Q37187292-74C25CB1-D776-4789-BF89-F11EF737BA5E

P2860

Q37187292-05F2C94A-5D62-4CB8-97D4-8D9F97190DC8

Q37187292-27F82DD3-6776-4E08-B881-FCAB50245582

Q37187292-2F2301F6-AFAA-423A-90DB-3D1A0C87851F

Q37187292-3153B7D5-B340-4DCA-B7AF-0D5F3569D1F4

Q37187292-32285536-7F8E-4C7C-ADC0-7286A122BB86

Q37187292-342B28AB-0B2C-44D8-B79A-8A6BB407D8BD

Q37187292-3C7926E0-4A2A-4BCE-A9A8-AAE46414512A

Q37187292-4F808841-2663-44C7-ADEA-3731E3E43FA3

Q37187292-65E1F263-35FB-4FC6-95F1-58BE64317E4C

Q37187292-6E1B58CA-849F-4351-870E-C4264CA91FF3

P304

Q37187292-D42D8FC1-487E-4FA2-9118-8C8C93534594

P31

Q37187292-536697A0-F47C-4D2E-942D-18F458A2A274

P356

Q37187292-017F7E8A-189C-43E3-8F90-0B2DF8A590F8

P407

Q37187292-548E2C10-1BF7-4439-AA09-91E18E4D7D8A

P478

Q37187292-0272D387-DDF9-4E2A-9BA8-98509B559E59

P50

Q37187292-C3726AD4-C209-48F0-9E54-2ED89235E600

Q37187292-D4FDF865-C49B-4DB4-9ED7-4191C65CE75F

P577

Q37187292-58FAD410-635D-41CA-8176-7830AE2070A6

P698

Q37187292-4B9F0E45-9103-4B86-8FBB-680841611FE7

P921

Q37187292-7F2D925E-AD33-4778-908A-849E01277FA6

P932

Q37187292-1C60A668-31B4-4FF5-91AB-109A2F229F3D

P356

P1433

Clinical Medicine: Oncology

P1476

Age, Neurological Status MRC S ...... a Treated by Chemoradiotherapy

@en

P2093

Antoine Petit

http://www.w3.org/2001/XMLSchema#string

Clotilde Verlut

http://www.w3.org/2001/XMLSchema#string

Elsa Curtit

http://www.w3.org/2001/XMLSchema#string

Emilie Bonnet

http://www.w3.org/2001/XMLSchema#string

Françoise Cattin

http://www.w3.org/2001/XMLSchema#string

Gabriel Viennet

http://www.w3.org/2001/XMLSchema#string

Guillaume Mouillet

http://www.w3.org/2001/XMLSchema#string

Joël Godard

http://www.w3.org/2001/XMLSchema#string

Joëlle Buffet-Miny

http://www.w3.org/2001/XMLSchema#string

Laurent Cals

http://www.w3.org/2001/XMLSchema#string

P2860

The 2007 WHO classification of tumours of the central nervous system

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Malignant gliomas in adults

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.

Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison.

Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series.

High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P304

77-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CMO.S38474

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27559302

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

4990148

http://www.w3.org/2001/XMLSchema#string